Drugs / Latanoprostene bunod
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VYZULTA | — | 2017-11-02 | fda.gov ↗ |
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01895985 | Jul → Aug 2013 | — | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01707381 | Nov 2012 → Dec 2013 | ocular hypertension, open-angle glaucoma | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT01223378 | Dec 2010 → Dec 2011 | — | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01895972 | Jul 2013 → Apr 2015 | glaucoma, ocular hypertension | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT01749904 | Jan 2013 → Jun 2015 | ocular hypertension, open-angle glaucoma | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT01749930 | Jan 2013 → May 2015 | ocular hypertension, open-angle glaucoma | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04140279 | May 2022 → Aug 2023 | ocular hypertension | Bausch & Lomb Incorporated | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03931317 | Dec 2018 → May 2021 | ocular hypertension, open-angle glaucoma | University of California, San Diego | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Latanoprostene bunod | “Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.” PMID 27210275 ↗ May 2016 |
| Known as | BOL-303259-X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01749904 ↗ |
| Known as | Latanoprosteno bunod | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364612 ↗ |
| Known as | LBN | “PURPOSE: To compare the intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) 0.024% with timolol maleate 0.5% in subjects with open-angle glaucoma (OAG) or...” PMID 27210275 ↗ May 2016 |
| Known as | NCX 116 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364612 ↗ |
| Known as | PF-3187207 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364612 ↗ |
| Known as | Vesneo | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364612 ↗ |
| Known as | Vyzulta | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364612 ↗ |
| Action | Activate | “prostaglandin F2α receptor agonist” PMID 26563323 ↗ Nov 20151“Prostanoid FP receptor agonist” CHEMBL2364612 ↗ |
| Modality | Small molecule | — CHEMBL2364612 ↗ |
| Route | Topical | “Subjects instilled one drop of study medication in the study eye” PMID 25488946 ↗ Dec 2014 |
| Target | PTGFR | “Prostanoid FP receptor agonist” CHEMBL2364612 ↗ |